

Breakthroughs in MASH Diagnosis and Management

A Liver Connect City Series

Stay at the forefront of liver health advancements and earn up to **3.0 AMA PRA Category 1 Credits™!**



**Saturday,
February 8, 2025**
8:30 AM–12:00 PM



Houston, TX
Houston Marriott West Loop
*1750 W Loop S
Houston, TX 77027*



Learn More & Register!

Speakers



Mazen Nouredin, MD, MHSc
Houston Methodist
Houston, TX



Rashmee Patil, MD
Pinnacle Clinical Research
Edinburg, TX



Grace Su, MD
University of Michigan
Ann Arbor, MI

Educational Objectives

- Assess the epidemiologic impact of the spectrum of SLD and MASLD
- Discuss the Use of NITs in MASLD Risk Stratification and Monitoring in clinical practice
- Explain initial treatment of MASLD with Lifestyle Modification and approved medication to manage cardio-metabolic risks (obesity and type 2 diabetes)
- Review data on the currently approved medication for MASH
- Review data about the most promising drugs in Phase 2 and 3 clinical trials of MASH



www.mashallianceeducation.org



info@mashallianceeducation.org



THE GLOBAL NASH COUNCIL | GHAPP | CLDF

Jointly provided by Medical Education Resources, the Chronic Liver Disease Foundation, Gastroenterology and Hepatology Advanced Practice Providers, and the Global NASH Council.



Supported by an educational grant from Madrigal Pharmaceuticals.